Technology
Converge Reports Fourth Quarter and Fiscal Year 2024 Results
Published
1 year agoon
By
TORONTO and GATINEAU, QC, March 5, 2025 /PRNewswire/ — Converge Technology Solutions Corp. (“Converge” or the “Company”) (TSX:CTS) (FSE:0ZB) (OTCQX:CTSDF) is pleased to provide its financial results for the three months and fiscal year ended December 31, 2024. All figures are in Canadian dollars unless otherwise stated.
Fourth Quarter 2024 Highlights (year-over-year, unless otherwise noted):
Gross sales1 of $1.11 billion, an increase of $27.4 million or 2.5%;Gross sales organic growth1 of 3.0% and gross profit organic growth1 of (0.0%);Revenue of $680.8 million, an increase of $29.7 million or 4.6%;Gross profit decreased 1.6% to $178.6 million, representing a gross margin of 26.7%;Adjusted EBITDA1 increased by 3.0% to $47.9 million;Cash from operating activities was $57.0 million, a decrease of $57.5 million, compared to $114.5 million for the comparative period in the prior year;Returned $20.6 million of capital to shareholders1 as compared to $4.7 million return of capital to shareholders in Q4 FY23; andReduced net debt1 by $14.5 million from $127.9 million at Q3 2024; maintaining a leverage ratio1 below 0.7x.
Fiscal Year 2024 Highlights (year-over-year, unless otherwise noted):
Gross sales1 of $4.12 billion, an increase of $82.8 million or 2.1%;Gross sales organic growth1 of 2.3% and gross profit organic growth1 of (0.7%);Revenue of $2.59 billion, a decrease of $113.1 million or (4.2%);Gross profit decreased 1.6% to $691.4 million, representing a gross margin of 26.7%;Adjusted EBITDA1 decreased by 1.7% to $167.3 million;Net loss of $181.0 million, an increase in loss of $174.6 million, driven by the non-cash impairment charge on the Germany segment of $176.1 million;Returned $82.3 million of capital to shareholders1 as compared to $23.5 million return of capital to shareholders for the comparative period in prior year;Cash from operating activities was $269.4 million, an increase of $39.9 million, compared to $229.5 million for the comparative period in the prior year; andReduced net debt1 by $96.4 million to $113.4 million, from $209.8 million at Q4 2023.
_________
1
This is a Non-IFRS measure (including non-IFRS ratio or supplementary financial measure) and not a recognized, defined or standardized measure under IFRS. See the “Non-IFRS Financial Measures” section of this press release for definitions, uses and a reconciliation of historical non-IFRS financial measures to the most directly comparable IFRS financial measures.
Financial Summary
Three months ended
December 31,
Fiscal year ended
December 31,
In $000s except per share amounts
2024
$
2023
$
2024
$
2023
$
Gross Sales1
1,106,055
1,078,663
4,120,717
4,037,921
Revenue
680,778
651,090
2,592,081
2,705,207
Gross profit (GP)
178,629
181,529
691,442
702,880
Gross profit (GP)%
26.2 %
27.9 %
26.7 %
26.0 %
Adjusted EBITDA1
47,885
46,505
167,315
170,294
Adjusted EBITDA as a % of GP1
26.8 %
25.6 %
24.2 %
24.2 %
Net loss
(9,174)
4,781
(180,986)
(6,393)
Adjusted net income1
45,586
38,214
130,289
108,399
Adjusted EPS1
0.23
0.19
0.66
0.53
Converge to be Acquired by H.I.G. Capital
On February 7, 2025, Converge announced that it had entered into an arrangement agreement (the “Arrangement Agreement”) with an affiliate of H.I.G. Capital (“H.I.G.”), whereby H.I.G will acquire all of the issued and outstanding common shares (the “Common Shares”) of the Company (the “Transaction”). Under the terms of the Arrangement Agreement, shareholders will receive $5.50 per Common Share in cash, other than Common Shares held by certain shareholders who enter into rollover equity agreements, representing approximately 56% and 57% respective premiums to the closing price and 30-day volume weighted average price of the shares on the TSX on February 6, 2025, the last trading day prior to the date of the announcement of the Transaction. The purchase price of the Transaction values Converge at an enterprise value of approximately C$1.3 billion. Upon completion of the Transaction, the Company intends to apply to delist the Common Shares from all public markets and cease to be a reporting issuer under Canadian securities laws.
The Transaction is to be considered by shareholders at a special meeting of shareholders to be held on April 10, 2025. A management information circular with respect to the matters to be considered at that meeting will be filed by Converge on SEDAR+ at www.sedarplus.ca, and will been mailed to shareholders.
As a result of the proposed Transaction, the Company will not be holding an earnings conference call and is suspending its practice of providing its outlook for revenue, gross profit and Adjusted EBITDA for the 2025 fiscal year. As part of the Arrangement Agreement, Converge has agreed that its regular quarterly dividend during the pendency of the Transaction will not be declared.
__________
1
This is a Non-IFRS measure (including non-IFRS ratio or supplementary financial measure) and not a recognized, defined or standardized measure under IFRS. See the “Non-IFRS Financial Measures” section of this press release for definitions, uses and a reconciliation of historical non-IFRS financial measures to the most directly comparable IFRS financial measures.
About Converge
Converge Technology Solutions Corp. is reimagining the way businesses think about IT—a vision driven by people, for people. Since 2017, we have focused on delivering outcomes-driven solutions that tackle human-centered challenges. As a services-led, software-enabled, IT & Cloud Solutions provider, we combine deep expertise, local connections, and global resources to deliver industry-leading solutions.
Through advanced analytics, artificial intelligence (AI), cloud platforms, cybersecurity, digital infrastructure, and workplace transformation, we empower businesses across industries to innovate, streamline operations, and achieve meaningful results. Our AIM (Advise, Implement, Manage) methodology ensures solutions are tailored to our customers’ specific needs, aligning with existing systems to drive success without complexity.
Discover IT reimagined with Converge—where innovation meets people. Learn more at convergetp.com.
Summary of Statements of Financial Position
(expressed in thousands of Canadian dollars)
December 31,
2024
$
December 31,
2023
$
Assets
Current
Cash
142,733
170,419
Trade and other receivables
1,000,573
803,652
Inventories
62,938
73,166
Prepaid expenses and other assets
30,728
26,528
1,236,972
1,073,765
Non-current
Investment in associates
4,795
–
Unbilled receivables and other assets
204,208
64,158
Property, equipment and right-of-use assets, net
69,696
75,488
Intangible assets, net
265,882
375,181
Goodwill
404,711
564,770
Total assets
2,186,264
2,153,362
Liabilities
Current
Trade and other payables
1,202,943
853,655
Other financial liabilities
39,882
54,095
Deferred revenue
81,109
59,325
Borrowings
639
1,664
Income taxes payable
–
9,286
1,324,573
978,025
Non-current
Accrued liabilities and other payables
184,514
60,339
Other financial liabilities
34,174
57,668
Borrowings
255,464
378,007
Deferred tax liabilities
28,804
67,168
Total liabilities
1,827,529
1,541,207
Shareholders’ equity
Common shares
555,521
599,434
Contributed surplus
16,532
10,970
Accumulated other comprehensive income
28,603
3,963
Deficit
(241,921)
(28,167)
Total equity attributable to shareholders of Converge
358,735
586,200
Non-controlling interest
–
25,955
358,735
612,155
Total liabilities and shareholders’ equity
2,186,264
2,153,362
Summary of Statements of Income and Comprehensive Income
(expressed in thousands of Canadian dollars)
Three months ended
December 31,
Fiscal year ended
December 31,
2024
$
2023
$
2024
$
2023
$
Revenue
Product
555,055
490,948
2,058,494
2,098,880
Service
125,723
160,142
533,587
606,327
Total revenue
680,778
651,090
2,592,081
2,705,207
Cost of sales
502,149
469,561
1,900,639
2,002,327
Gross profit
178,629
181,529
691,442
702,880
Selling, general and administrative expenses
134,040
137,451
534,918
541,118
Income before the following
44,589
44,078
156,524
161,762
Depreciation and amortization
20,283
29,212
89,665
111,451
Finance expense, net
8,098
10,355
30,979
41,225
Acquisition, integration, restructuring and other
5,737
2,679
16,429
13,648
Change in fair value of contingent consideration
6,293
5,464
10,582
14,673
Share-based compensation
1,185
954
5,858
3,692
Other loss (income), net
237
(132)
1,357
(4,362)
Loss on loss of control of Portage
–
–
117
–
Loss from investment in associates
23,962
–
25,930
–
Impairment loss – Germany segment
–
–
176,124
–
Loss before income taxes
(21,206)
(4,454)
(200,517)
(18,565)
Income tax recovery
(12,032)
(9,235)
(19,531)
(12,172)
Net (loss) income
(9,174)
4,781
(180,986)
(6,393)
Net (loss) income attributable to:
Shareholders of Converge
(9,174)
5,861
(177,713)
(1,448)
Non-controlling interest
–
(1,080)
(3,273)
(4,945)
(9,174)
4,781
(180,986)
(6,393)
Other comprehensive (loss) income
Exchange differences on translation of foreign operations
15,594
916
24,640
(9,745)
Comprehensive (loss) income
6,420
5,697
(156,346)
(16,138)
Comprehensive (loss) income attributable to:
Shareholders of Converge
6,420
6,777
(153,073)
(11,193)
Non-controlling interest
–
(1,080)
(3,273)
(4,945)
6,420
5,697
(156,346)
(16,138)
Adjusted EBITDA1
47,885
46,505
167,315
170,294
Adjusted EBITDA as a % of gross profit1
26.8 %
25.6 %
24.2 %
24.2 %
Summary of Statements of Cash Flows
(expressed in thousands of Canadian dollars)
Three months ended
December 31,
Fiscal year ended
December 31,
2024
2023
2024
2023
$
$
$
$
Cash flows from operating activities
Net loss
(9,174)
4,781
(180,986)
(6,393)
Adjustments to reconcile net loss to net cash from operating activities
Depreciation and amortization
23,579
31,369
100,456
119,983
Unrealized foreign exchange loss (gain)
197
(4)
1,077
(2,822)
Share-based compensation
1,185
954
5,858
3,692
Finance expense, net
8,098
10,355
30,979
41,225
(Loss) gain on sale of property and equipment
14
335
87
(263)
Change in fair value of contingent consideration
6,293
5,464
10,582
14,673
Impairment loss – Germany segment
–
–
176,124
–
Loss on loss of control of Portage
–
–
117
–
Loss from investment in associates
23,962
–
25,930
–
Income tax recovery
(12,032)
(9,235)
(19,531)
(12,172)
42,122
44,289
150,693
157,923
Changes in non-cash working capital items
16,822
71,888
148,464
90,746
58,944
116,177
299,157
248,669
Income taxes paid
(1,971)
(1,696)
(29,776)
(19,129)
Cash from operating activities
56,973
114,481
269,381
229,540
Cash flows from (used in) investing activities
Purchase of (proceeds from) property, equipment and intangible assets
206
(2,038)
(1,442)
(10,828)
Proceeds on disposal of property and equipment
–
7
–
3,756
Payment of contingent consideration
(5,971)
(1,238)
(25,299)
(24,773)
Payment of deferred consideration
–
–
(12,375)
(41,114)
Payment of NCI liability
–
–
–
(30,967)
Cash used in investing activities
(5,765)
(3,269)
(39,116)
(103,926)
Cash flows (used in) from financing activities
Transfers from restricted cash
–
3,162
–
5,230
Interest paid
(5,637)
(7,938)
(23,767)
(33,724)
Dividends paid
(2,852)
(2,042)
(10,777)
(6,156)
Payment of lease liabilities
(4,967)
(5,427)
(19,760)
(20,626)
Repurchase of common shares
(17,713)
(2,094)
(71,506)
(17,388)
Stock options exercised
–
–
875
–
Repayment of notes payable
–
(40)
(39)
(159)
Net repayment of borrowings
(61,502)
(29,882)
(139,848)
(40,475)
Cash used in financing activities
(92,671)
(44,261)
(264,822)
(113,298)
Net change in cash during the period
(41,463)
66,951
(34,557)
12,316
Effect of foreign exchange on cash
3,732
(1,753)
7,945
(1,787)
Cash derecongnized on loss of control of Portage
–
–
(1,074)
–
Cash, beginning of the period
180,464
105,221
170,419
159,890
Cash, end of the period
142,733
170,419
142,733
170,419
__________
1
This is a Non-IFRS measure (including non-IFRS ratio or supplementary financial measure) and not a recognized, defined or standardized measure under IFRS. See the “Non-IFRS Financial Measures” section of this press release for definitions, uses and a reconciliation of historical non-IFRS financial measures to the most directly comparable IFRS financial measures.
Non-IFRS Financial Measures
This press release refers to certain performance indicators including Adjusted EBITDA, gross sales, gross sales organic growth, return of capital, net debt, leverage ratio, adjusted net income (“Adjusted Net Income”) and adjusted earnings per share (“Adjusted EPS”) that do not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies. Management believes that these measures are useful to most shareholders, creditors, and other stakeholders in analyzing the Company’s operating results and can highlight trends in its core business that may not otherwise be apparent when relying solely on IFRS financial measures. The Company also believes that securities analysts, investors and other interested parties frequently use non-IFRS measures in the evaluation of issuers.
Management also uses non-IFRS measures in order to facilitate operating performance comparisons from period to period, prepare annual operating budgets and assess the ability to meet capital expenditure and working capital requirements. These non-IFRS financial measures should not be considered as an alternative to the consolidated income (loss) or any other measure of performance under IFRS. Investors are encouraged to review the Company’s financial statements and disclosures in their entirety, are cautioned not to put undue reliance on non-IFRS measures and view them in conjunction with the most comparable IFRS financial measures.
Please see “Non-IFRS Financial & Supplementary Financial Measures” and “Summary of Consolidated Financial Results” in the Company’s most recent Management’s Discussion and Analysis, which is available on the Company’s profile on SEDAR+ at www.sedarplus.ca, for further details on certain non-IFRS measures, which information is incorporated by reference herein.
Adjusted EBITDA
Adjusted EBITDA represents net income or loss adjusted to exclude amortization, depreciation, net finance expense, foreign exchange gains and losses, other expenses and income, share-based compensation expense, income tax expense or recovery, change in fair value of contingent consideration, impairment loss, gain or loss on loss of control of subsidiary, income or loss from investment in associates and acquisition, integration, restructuring and other expenses. Acquisition and transaction related costs primarily consists of acquisition-related compensation tied to continued employment of pre-existing shareholders of the acquiree not included in the total purchase consideration and professional fees. Integration costs primarily consist of professional fees incurred related to integration of acquisitions completed. Restructuring costs mainly represent employee exit costs as a result of synergies created from acquisitions and organizational changes.
Adjusted EBITDA is not a recognized, defined, or standardized measure under IFRS. The Company’s definition of Adjusted EBITDA will likely differ from that used by other companies and therefore comparability may be limited.
Adjusted EBITDA should not be considered a substitute for or in isolation from measures prepared in accordance with IFRS.
The IFRS measure most directly comparable to Adjusted EBITDA presented in the Company’s financial statements is net (loss) income before taxes.
The Company has reconciled Adjusted EBITDA to the most comparable IFRS financial measure as follows:
Three months ended
December 31,
Fiscal year ended
December 31,
In $000s
2024
$
2023
$
2024
$
2023
$
Net (loss) income before taxes
(21,206)
(4,454)
(200,517)
(18,565)
Depreciation and amortization
20,283
29,212
89,665
111,451
Depreciation included in cost of sales
3,296
2,427
10,791
8,532
Finance expense, net
8,098
10,355
30,979
41,225
Acquisition, integration, restructuring and other
5,737
2,679
16,429
13,648
Change in fair value of contingent consideration
6,293
5,464
10,582
14,673
Share-based compensation
1,185
954
5,858
3,692
Other loss (income), net
237
(132)
1,357
(4,362)
Loss on loss of control of Portage
–
–
117
–
Loss from investment in associates
23,962
–
25,930
–
Impairment loss – Germany segment
–
–
176,124
–
Adjusted EBITDA
47,885
46,505
167,315
170,294
Adjusted EBITDA as a % of Gross Profit
The Company believes that Adjusted EBITDA as a % of gross profit is a useful measure of the Company’s operating efficiency and profitability. This is calculated by dividing Adjusted EBITDA by gross profit.
Adjusted Net Income and Adjusted EPS
Adjusted Net Income represents net income or loss adjusted to exclude acquisition, integration, restructuring and other expenses, change in fair value of contingent consideration, impairment loss, gain or loss on loss of control of subsidiary, income or loss from investment in associates, amortization of acquired intangible assets, unrealized foreign exchange gain or loss, and share-based compensation. The Company believes that Adjusted Net Income is a more useful measure than net income as it excludes the impact of one-time, non-cash and/or non-recurring items that are not reflective of Converge’s underlying business performance. Adjusted EPS is calculated by dividing Adjusted Net Income by the total weighted average shares outstanding on a basic and diluted basis. The IFRS measure most directly comparable to Adjusted Net Income presented in the Company’s financial statements is net income (loss) and net income (loss) per share. The Company has provided a reconciliation to the most comparable IFRS financial measure as follows:
Three months ended
December 31,
Fiscal year ended
December 31,
In $000s except per share amounts
2024
$
2023
$
2024
$
2023
$
Net loss
(9,174)
4,781
(180,986)
(6,393)
Acquisition, integration, restructuring and other
5,737
2,679
16,429
13,648
Change in fair value of contingent consideration
6,293
5,464
10,582
14,673
Amortization on intangibles
17,386
24,468
75,158
87,259
Foreign exchange loss (gain)
197
(132)
1,077
(4,480)
Share-based compensation
1,185
954
5,858
3,692
Loss on loss of control or Portage
–
–
117
–
Loss from investment in associates
23,962
–
25,930
–
Impairment loss- Germany segment
–
–
176,124
–
Adjusted Net Income
45,586
38,214
130,289
108,399
Adjusted EPS – Basic
0.23
0.19
0.66
0.53
Return of capital
The Company calculates return of capital to shareholders as the total of cash used in dividend payments and share repurchases.
Net Debt
The Company calculates net debt1 as current and non-current borrowings less cash.
Leverage Ratio
The Company defines leverage ratio as net debt (current and non-current borrowings less cash) divided by trailing twelve months Adjusted EBITDA.
Gross sales and gross sales organic growth
Gross sales, which is a non-IFRS measure, reflects the gross amount billed to customers, adjusted for amounts deferred or accrued. The Company believes gross sales is a useful alternative financial metric to net revenue, the IFRS measure, as it better reflects volume fluctuations as compared to net revenue. Under the applicable IFRS 15 ‘principal vs agent’ guidance, the principal records revenue on a gross basis and the agent records commission on a net basis. In transactions where Converge is acting as an agent between the customer and the vendor, net revenue is calculated by reducing gross sales by the cost of sale amount.
The Company has provided a reconciliation of gross sales to revenue, which is the most comparable IFRS financial measure, as follows:
Three months ended
December 31,
Fiscal year ended
December 31,
In $000s
2024
$
2023
$
2024
$
2023
$
Product
811,839
719,974
2,898,039
2,747,172
Managed services and professional services
119,128
138,001
472,535
522,827
Maintenance, support, and cloud solutions
175,088
220,688
750,143
767,922
Gross sales
1,106,055
1,078,663
4,120,717
4,037,921
Less: adjustment for sales transacted as agent
425,277
427,573
1,528,636
1,332,714
Revenue
680,778
651,090
2,592,081
2,705,207
Organic growth
The Company measures organic growth on a quarterly and year-to-date basis, at the gross sales and gross profit levels, and includes the contributions under Converge ownership in the current and comparative period(s). In calculating organic growth, the Company therefore deducts gross sales and gross profit generated from all corresponding prior period comparable pre-acquisition period(s) from the current reporting period(s) included in the consolidated results.
Organic growth calculation for the three months and fiscal year ended December 31, 2024, deducts gross sales and gross profits from Portage CyberTech Inc. (“Portage”) for the three and six months ended December 31, 2023 due to deconsolidation of Portage on June 27, 2024.
Gross profit organic growth is calculated by deducting prior period gross profit, as reported in the Company’s public filings, from current period gross profit for the same portfolio of companies. Gross profit organic growth percentage is calculated by dividing organic growth by prior period reported gross profit.
Three months ended
December 31,
Fiscal year ended
December 31,
In $000s
2024
$
2023
$
2024
$
2023
$
Gross sales
1,106,055
1,078,663
4,120,717
4,037,921
Less: gross sales from companies not owned in comparative period
–
17,286
–
611,045
Gross sales of companies owned in comparative period
1,106,055
1,061,377
4,120,717
3,426,876
Less: prior period gross sales(i)
1,074,132
956,803
4,028,409
3,090,981
Organic Growth – $
31,923
104,574
92,308
335,895
Organic Growth – %
3.0 %
10.9 %
2.3 %
10.9 %
(i)
For the three months ended December 31, 2024, Portage prior period gross sales of $4,531 is excluded and for the fiscal year ended December 31, 2024, Portage prior period gross sales1 of $9,512 is excluded.
Gross profit organic growth is calculated by deducting prior period gross profit, from current period gross profit for the same portfolio of companies. Gross profit organic growth percentage is calculated by dividing organic growth by prior period reported gross profit.
Three months ended
December 31,
Fiscal year ended
December 31,
In $000s
2024
$
2023
$
2024
$
2023
$
Gross profit
178,629
181,529
691,442
702,880
Less: gross profit from companies not owned in comparative period
–
3,032
–
107,295
Gross profit of companies owned in comparative period
178,629
178,497
691,442
595,585
Less: Prior period gross profit(i)
178,656
168,916
696,556
550,767
Organic Growth – $
(27)
9,581
(5,114)
44,818
Organic Growth – %
–
5.7 %
(0.7 %)
8.1 %
(i)
For the three months ended December 31, 2024, Portage prior period gross profit of $2,873 is excluded and for the fiscal year ended December 31, 2024, Portage prior period gross profit of $6,324 is excluded.
Forward-Looking Information
This press release contains certain “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities legislation regarding Converge and its business. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected” “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”. “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements.
Specifically, statements regarding the Transaction, anticipated timing of the special meeting of shareholders in respect of the Transaction, the delisting from the TSX and ceasing to be a to be a reporting issuer under Canadian securities laws , are considered forward-looking information. The foregoing demonstrates Converge’s objectives, which are not forecasts or estimates of its financial position, but are based on the implementation of its strategic goals, growth prospects, and growth initiatives. The forward-looking information are based on management’s opinions, estimates and assumptions, including, but not limited to: assumptions as to the ability of the parties to the Transaction to receive, in a timely manner and on satisfactory terms, the necessary regulatory, court and shareholder approvals; the ability of the parties to satisfy, in a timely manner, the other conditions for the completion of the Transaction, and other expectations and assumptions concerning the proposed Transaction. The anticipated dates indicated may change for a number of reasons, including the necessary regulatory and court approvals or the necessity to extend the time limits for satisfying the other conditions for the completion of the proposed Transaction.
While these opinions, estimates and assumptions are considered by the Company to be appropriate and reasonable in the circumstances as of the date of this press release, they are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance, or achievements to be materially different from those expressed or implied by such forward-looking information.
The forward looking information are subject to significant risks including, without limitation: the failure of the parties to obtain the necessary regulatory and court approvals; failure of the parties to obtain such approvals or satisfy such conditions in a timely manner; H.I.G’s ability to complete the anticipated debt and equity financing as contemplated by applicable commitment letters or to otherwise secure favourable terms for alternative financing; significant transaction costs or unknown liabilities; the ability of the Board to consider and approve, subject to compliance by the Company with its obligations under the Arrangement Agreement, a superior proposal for the Company; the market price of Common Shares and business generally; potential legal proceedings relating to the Transaction and the outcome of any such legal proceeding; or the occurrence of any event, change or other circumstances that could give rise to the termination of the Arrangement Agreement and general economic conditions. Failure to obtain the necessary shareholder, regulatory and court approvals, or the failure of the parties to otherwise satisfy the conditions for the completion of the Transaction or to complete the Transaction, may result in the Transaction not being completed on the proposed terms or at all. In addition, if the Transaction is not completed, and the Company continues as an independent entity, there are risks that the announcement of the Transaction and the dedication of substantial resources by the Company to the completion of the Transaction could have an impact on its business and strategic relationships, including with future and prospective employees, customers, suppliers and partners, operating results and activities in general, and could have a material adverse effect on its current and future operations, financial condition and prospects. If any of these risks or uncertainties materialize, or if the opinions, estimates or assumptions underlying the forward-looking information prove incorrect, actual results or future events might vary materially from those anticipated in the forward-looking information. Although the Company has attempted to identify important risk factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other risk factors not presently known to the Company or that the Company presently believes are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information.
There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. No forward-looking statement is a guarantee of future results. Accordingly, you should not place undue reliance on forward-looking information, which speaks only as of the date made. The forward-looking information contained in this press release represents the company’s expectations as of the date specified herein, and are subject to change after such date. However, the Company disclaims any intention or obligation or undertaking to update or revise any forward-looking information or to publicly announce the results of any revisions to any of those statements, whether as a result of new information, future events or otherwise, except as required under applicable securities laws.
All of the forward-looking information contained in this press release is expressly qualified by the foregoing cautionary statements.
For further information contact: Converge Technology Solutions Corp., Email: investors@convergetp.com, Phone: 416-360-1495
View original content:https://www.prnewswire.co.uk/news-releases/converge-reports-fourth-quarter-and-fiscal-year-2024-results-302393686.html
You may like
Technology
HelloNation Article Highlights Sterile Compounding and Medication Safety With Insights From Compounding Pharmacist Expert Laura Temple
Published
54 minutes agoon
July 21, 2026By
The article explains how sterile compounded medications are prepared to reduce the risk of contamination and support safe, customized treatments.
AZLE, Texas, July 21, 2026 /PRNewswire/ — What does sterile compounding mean for medication safety? HelloNation has published an article explaining how sterile compounding helps pharmacies prepare highly specialized medications while adhering to strict contamination-prevention procedures.
The article features insights from Laura Temple, Compounding Pharmacist Expert and Owner of Laura’s Pharmacy in Azle, Texas. It explains that sterile compounding is a specialized process for preparing medications in carefully controlled environments designed to reduce the risk of contamination. Sterile compounded medications are often used for injections, eye drops, IV medications, and other therapies that require the highest levels of cleanliness and precision.
The HelloNation article explains that sterile compounded medications differ from commercially manufactured drugs because they are prepared individually for a patient’s unique medical needs. Physicians may prescribe compounded prescriptions when a patient requires a customized dosage, a combination medication, or a treatment not commercially available. Because these medications often bypass the body’s natural defenses, medication safety depends on strict preparation standards throughout the compounding process.
The article describes how pharmacies that provide sterile compounding rely on cleanroom environments equipped with filtered-air systems, specialized equipment, and contamination-prevention protocols. Pharmacists and technicians follow detailed gowning, sterilization, and handwashing procedures before handling medication ingredients. These measures are designed to support medication safety by limiting exposure to bacteria, particles, and other contaminants.
According to the article, environmental monitoring also plays a critical role in sterile compounding. Temperature control, air quality testing, and routine equipment inspections help maintain consistent preparation standards. The article notes that sterile compounded medications may undergo additional quality assurance checks before being dispensed to patients. These procedures help support both treatment effectiveness and patient safety.
The HelloNation article also explains that pharmacies performing sterile compounding are expected to follow USP guidelines established for sterile preparation. These USP guidelines outline requirements for cleanroom pharmacy operations, environmental testing, employee training, and quality assurance practices. The article emphasizes that maintaining compliance with USP guidelines helps reinforce contamination prevention and consistent preparation standards for compounded prescriptions.
Patients seeking sterile compounded medications may also look for pharmacies that participate in accreditation programs or are overseen by state boards. The article explains that these programs review safety procedures, documentation practices, and facility standards to help maintain medication safety. Regular environmental monitoring and staff competency evaluations are also identified as important safeguards in sterile compounding operations.
The article further explains that communication between pharmacists, healthcare providers, and patients remains an important part of safe compounded prescriptions. Compounding pharmacists review prescriptions carefully, confirm dosing instructions, and evaluate ingredient compatibility before preparation begins. This collaborative approach supports medication safety by reducing the risk of errors and ensuring treatments meet individual patient needs.
The article concludes that sterile compounding continues to play an important role in healthcare, particularly for patients requiring customized therapies that are unavailable through traditional manufacturing channels. Whether preparing IV medications, injectable therapies, or other sterile compounded medications, pharmacies rely on contamination prevention procedures and strict preparation standards to support patient care. The article notes that understanding how sterile compounding works can help patients feel more informed about the safety measures involved in preparing specialized medications.
What Sterile Compounding Means for Medication Safety features insights from Laura Temple, a compounding pharmacist expert at Laura’s Pharmacy in Azle, Texas, on HelloNation.
About HelloNation
HelloNation is America’s Good News Network, a premier media platform built on the idea that good news travels faster when real people tell real stories. Through its community-focused publications and innovative “edvertising” approach, HelloNation delivers content that informs, inspires, and spotlights the leaders making a meaningful impact in their communities.
View original content to download multimedia:https://www.prnewswire.com/news-releases/hellonation-article-highlights-sterile-compounding-and-medication-safety-with-insights-from-compounding-pharmacist-expert-laura-temple-302831275.html
SOURCE HelloNation
Technology
CIOs Forced to Rethink Manual Compliance Processes as Regulatory Complexity Rises, Says Info-Tech Research Group
Published
54 minutes agoon
July 21, 2026By
Regulatory demands are increasing in volume, complexity, and speed, leaving many organizations reliant on fragmented, manual approaches that slow response times and increase risk. New insights from Info-Tech Research Group show that organizations need to adopt more structured and scalable approaches to keep pace with regulatory change. The firm’s recently published blueprint, Build a Regulatory IT Response Engine, provides frameworks, tools, and step-by-step guidance to help organizations translate regulatory requirements into actionable IT controls and prioritized initiatives.
ARLINGTON, Va., July 21, 2026 /PRNewswire/ — Growing regulatory pressure across jurisdictions is forcing organizations to rethink how they interpret, prioritize, and execute compliance requirements. Many IT teams continue to operate with inconsistent processes and limited coordination, resulting in delayed initiatives and increased exposure to financial and reputational risk. Info-Tech’s blueprint, Build a Regulatory IT Response Engine, introduces a coordinated and repeatable approach to help IT leaders operationalize compliance and improve execution outcomes.
Info-Tech’s findings indicate that while organizations recognize the need for faster and more consistent regulatory response, they continue to face barriers such as fragmented interpretation of requirements, weak prioritization, and limited scalability. AI-enabled tools can help streamline analysis and accelerate response planning, but without a coordinated approach grounded in governance and human oversight, those benefits are difficult to realize.
“Regulatory response is becoming too complex to manage through disconnected, manual processes,” says Ahmad Jowhar, senior research analyst at Info-Tech Research Group. “IT leaders need a repeatable way to interpret requirements, prioritize action, and use AI to accelerate planning without losing the governance and oversight needed to execute effectively.”
Key Challenges IT Leaders Face in Regulatory Response
Despite ongoing investments in compliance, organizations continue to face systemic challenges that hinder effective execution. Info-Tech’s blueprint highlights several areas where IT and compliance leaders struggle most:
Fragmented and manual processes that slow regulatory interpretation and response.Inconsistent application of regulatory requirements across teams and jurisdictions.Poor prioritization of IT initiatives, leading to missed deadlines and duplicated effort.Limited scalability to manage increasing regulatory volume and complexity.Misalignment between compliance activities and broader business priorities.
Info-Tech’s Framework for Building a Regulatory IT Response Engine
To address these challenges, Info-Tech recommends a structured, AI-enabled approach that improves consistency, speed, and scalability. The firm’s Build a Regulatory IT Response Engine blueprint outlines the following key priorities for IT leaders:
Define the regulatory landscape: Establish organizational context, governance structures, and a centralized inventory of applicable regulations.Translate requirements into IT controls: Use AI-enabled analysis and structured assessments to convert regulatory obligations into actionable controls.Prioritize IT initiatives: Align initiatives based on cost, effort, impact, and regulatory timelines to reduce execution risk.Build and communicate a roadmap: Develop a clear, resource-aligned roadmap to guide execution and stakeholder alignment.Establish a repeatable process: Continuously monitor, adapt, and refine regulatory response capabilities to maintain compliance over time.
Organizations that adopt this structured approach can move from reactive compliance efforts to a more proactive and scalable model that shortens response timelines, reduces manual effort, and strengthens execution.
The firm’s Build a Regulatory IT Response Engine blueprint includes practical tools such as a Regulation Inventory Tool, a Regulatory Response IT Action Plan Tool, a Communication Deck Template, and a Compliance Program Framework. By applying these resources, IT leaders can standardize regulatory responses, improve prioritization, and help ensure compliance initiatives are executed on time and in alignment with business priorities.
For exclusive and timely commentary from Info-Tech’s experts, including Ahmad Jowhar, and access to the complete Build a Regulatory IT Response Engine blueprint, please contact pr@infotech.com.
About Info-Tech Research Group
Info-Tech Research Group is the “get things done” partner for over 30,000 IT, HR, and marketing leaders worldwide. The fastest growing research and advisory firm, Info-Tech enables leaders to make well-informed decisions and transform their organizations through AI, strategic foresight, step-by-step methodologies, practical tools, industry-leading advisory, and training programs. For nearly 30 years, tens of thousands of private and public organizations have trusted Info-Tech to lead their most important initiatives through periods of change and deliver outcomes that truly matter.
To learn more about Info-Tech’s HR research and advisory services, visit McLean & Company, and for data-driven software buying insights and vendor evaluations, visit the firm’s SoftwareReviews platform.
Media professionals can register for unrestricted access to research across IT, HR, and software and hundreds of industry analysts through the firm’s Media Insiders program. To gain access, contact pr@infotech.com.
For information about Info-Tech Research Group or to access the latest research, visit infotech.com and connect via LinkedIn and X.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cios-forced-to-rethink-manual-compliance-processes-as-regulatory-complexity-rises-says-info-tech-research-group-302831286.html
SOURCE Info-Tech Research Group
Technology
Atomera to Announce Second Quarter 2026 Financial Results and Host Webinar on Tuesday, August 4, 2026
Published
54 minutes agoon
July 21, 2026By
LOS GATOS, Calif., July 21, 2026 /PRNewswire/ — Atomera Incorporated (NASDAQ: ATOM), a semiconductor materials and technology licensing company, announced today that it plans to release its second quarter 2026 financial results after the market closes on Tuesday, Aug. 4, 2026.
The company will host a live video Zoom webinar at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) on Tuesday, Aug. 4, 2026, to discuss the results. The live webinar can be accessed through Atomera’s investor relations website at https://ir.atomera.com. A replay of the webcast will be available for 12 months. To pre-register for the webinar, use the following link.
https://atomera.zoom.us/webinar/register/WN_OJFbTWe1SIyV69LLdDadCw
About Atomera
Atomera Incorporated is a semiconductor materials and technology licensing company focused on deploying its proprietary, silicon-proven technology into the semiconductor industry. Atomera has developed Mears Silicon Technology™ (MST®), which increases performance and power efficiency in semiconductor transistors. MST can be implemented using equipment already deployed in semiconductor manufacturing facilities and is complementary to other nano-scaling technologies already in the semiconductor industry roadmap. More information can be found at www.atomera.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/atomera-to-announce-second-quarter-2026-financial-results-and-host-webinar-on-tuesday-august-4-2026-302830602.html
SOURCE Atomera Incorporated
HelloNation Article Highlights Sterile Compounding and Medication Safety With Insights From Compounding Pharmacist Expert Laura Temple
CIOs Forced to Rethink Manual Compliance Processes as Regulatory Complexity Rises, Says Info-Tech Research Group
Atomera to Announce Second Quarter 2026 Financial Results and Host Webinar on Tuesday, August 4, 2026
Send Rakhi to UK swiftly with UK Gifts Portal
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
New Gooseneck Omni Antennas Offer Enhanced Signals in a Durable Package
Why You Should Build on #NEAR – Co-founder Illia Polosukhin at CV Labs
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
NEAR End of Year Town Hall 2021: The Open Web World, MetaBUILD 2 Hackathon and 2021 recap
Trending
-
Coin Market5 days agoBitcoin outlook improves amid 6% weekly gain: Can BTC bulls push higher?
-
Technology5 days agoTimed with the Canton Fair, Connexion ShenZhen 2026 Unveils Major Fourth-Edition Upgrades as a Greater Bay Area Mega Sourcing Event
-
Coin Market4 days agoThe British Virgin Islands are a top crypto hub no one ever talks about: Here’s why
-
Technology4 days agoGlobal Times: China sends fresh signal on global AI cooperation at WAIC
-
Coin Market5 days agoTrump teleprompter operator made $100K betting on Kalshi markets tied to speeches: ABC
-
Technology5 days agoGrand Bargain Project Announces Procedural Change that Will Turn Congress into a Problem-Solving Institution Within Days
-
Technology5 days agoDrake Expands End-to-End Professional Services with Launch of Drake Audit Defense™
-
Technology5 days agoTexas Instruments board declares third quarter 2026 quarterly dividend
